mavrilimumab: 40% adverse events??? https://p
Post# of 148173
https://pubmed.ncbi.nlm.nih.gov/28213566/
here is a mavrilimumab phase2B for rheumatoid arthritis with 300 patients.
40-50% of mavrilimumab patients have "adverse events" but I have no clue what that means, nor how to compare it to leronlimab.